Sunday 18 October 2026
Export PMVP’s income statement to Excel — free account
PMV Pharmaceuticals, Inc.
PMVP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.1% and free cash flow grew 20.3%, each against the same quarter a year earlier.
1.21
0.08
−6.20%
Follow PMVP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
10.76 | 10.09 | 11.14 | 7.70 |
Net Debt/EBITDA |
5.57 | 5.73 | 4.83 | 4.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.94 | 0.95 | 1.09 | 0.81 | |
Capex/Depreciation |
0.00 | 0.03 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.37) | (0.33) | (0.37) | (0.27) | |
Cash per Share |
2.44 | 2.15 | 1.75 | 1.49 | |
Shareholders Equity per Share |
2.28 | 1.99 | 1.65 | 1.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.28 | 1.99 | 1.65 | 1.34 | |
Free Cash Flow |
(19.82) | (17.20) | (19.68) | (14.58) | |
Working Capital |
120.15 | 103.81 | 87.19 | 70.84 | |
Capital Expenditures |
0.00 | (0.01) | — | — | |
Net Current Asset Value |
119.60 | 103.38 | 87.19 | 70.84 | |
| Other line items | |||||
Quick Ratio |
10.50 | 9.89 | 10.88 | 7.52 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.37) | (0.33) | (0.37) | (0.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.73 | 4.87 | 2.61 | 2.31 | |
Average Assets |
178.67 | 153.93 | 133.59 | 117.46 | |
Average Common Equity |
159.45 | 140.40 | 124.04 | 106.05 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates